NCT00004853View on ClinicalTrials.gov

Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 3, 2000

Primary Completion Date

May 20, 2009

Study Completion Date

May 20, 2009

Conditions
Ewing's SarcomaRhabdomyosarcomaMPNSTSynovial SarcomaHigh-risk Sarcoma
Interventions
BIOLOGICAL

Filgrastim

5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC \>=10,000/microliter

BIOLOGICAL

Filgrastim-SD/01

100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00004853 - Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy | Biotech Hunter | Biotech Hunter